PRO302

About Prolifagen Therapeutics

Prolifagen Therapeutics is pioneering a novel microRNA therapeutic approach, PRO302, designed to stimulate cardiomyocyte proliferation and regenerate heart muscle post-heart attack, moving beyond current standards of care that manage symptoms but do not repair damage. The company is led by a seasoned management team with deep experience in life sciences, cardiology, and company building. Operating in the massive and growing cardiovascular disease market, Prolifagen targets a transformative shift from disease management to true cardiac repair, though it faces the inherent risks of early-stage drug development and a complex competitive landscape.

Therapeutic Areas